Patent Law Archives | Page 21 of 22

This image depicts a person holding a placard reading GILEAD 1,000 per Pill, Shame. This image is relevant as Gilead had filed for a patent for the same medicine in India for the same price. Click on the image for more information

‘Killead’s Patent Application Killed by the Indian Patent Office!

Gilead Sciences was rejected patent for its blockbuster drug Sofosbuvir, a new Hepatitis C drug by the India Patent Office in a major decision taken on 13 January 2015. The drug is branded under the name Sovaldi. Gilead had priced the drug at US$84,000 for a treatment course, or $1,000 per pill in the US and had received a regulatory approval in US in 2013. The patent application (6087/DELNP/2005) for the drug was opposed by the Indian generic company Natco; Medicines,…

January 29, 2015 BananaIP Reporter Intellectual Property, Patents 0Comment 896Views 0Like

ShareFacebook

Roche’s backbone rendered brittle by Indian Patent Office

The Chennai Patent Office revoked Hoffmann-La-Roche’s patent on its osteoporosis drug, Bonviva, in response to post grant opposition filed by Indian drug maker, Cipla Global Ltd. The drug in question comprises Ibandronate Sodium, used to treat patients suffering from metastatic cancer, associated skeletal fractures and osteoporosis and also for the treatment and prevention of osteoporosis in post-menopausal women. Osteoporosis is the progressive bone disease caused by decrease in bone mass making bones extremely weak and fragile, leading to increased risk of…

January 16, 2015 BananaIP Reporter Intellectual Property, Patents 0Comment 768Views 0Like

ShareFacebook

The image depicts some tablets inside a glass. This image is relevant as Drug Humria was not granted Patent in India. Click on the image for more information

Drug Humira turns Rheumatic for Abbott Biotechnology

The Indian Patent Office on December 31, 2014 set aside its order of granting a Patent to Abbott Biotechnology for its drug, Humira, in light of pre-grant opposition filed by Glenmark Pharmaceuticals. In November, 2003, Abbott had filed a patent application No. 526/DELNP/2005 for its drug named Humira, a formulation of human antibodies for treating Rheumatoid Arthritis. Glenmark filed a pre-grant opposition to this application in September, 2008. Since this was not brought to the notice of the Controller, Patent…

January 13, 2015 BananaIP Reporter Intellectual Property, Patents 0Comment 945Views 0Like

ShareFacebook

RPX acquires patents owned by Apple’s Rockstar Consortium for US$ 900M

American patent risk management company, RPX Corp., entered into an agreement to acquire around 4,000 patents owned by Rockstar, a consortium led by Apple Inc. and other firms for US$ 900M. Rockstar was created as a patent holding entity in 2011 by technology bigwigs like Apple, Microsoft, Blackberry, Sony and Ericsson, with the intent of purchasing the 6,000 patents from the Nortel Network Corp., for US$ 4.5B, following its bankruptcy. About 2,000 of the most valuable patents have already been distributed…

January 9, 2015 BananaIP Reporter Intellectual Property, IP Commercialization/Licensing, Patents 0Comment 907Views 0Like

ShareFacebook

This image depicts Tablets of different colors. This image is relevant as there is a Patent Infringement dispute between Aurobindo Pharma and Astrazeneca. Click on the image for more information.

Astrazeneca to retain Sweetness of Onglyza

Aurobindo Pharma, USA, has been dragged to the Court for patent infringement by Astrazeneca. The suit filed is against the ANDA (Abbreviated New Drug Application) filed by Aurobindo Pharma with the USFDA with regard to seeking the market approval for Saxagliptin hydrochloride tablets before the expiry of its US patent. Aurobindo Pharma plans to market the generic versions of Saxagliptin hydrochloride tablets of 2.5 mg and 5 mg strengths. Astrazeneca is the sole marketer of Saxagliptin hydrochloride tablets having got…

January 8, 2015 BananaIP Reporter Intellectual Property, Patents 0Comment 766Views 0Like

ShareFacebook

Patent licensing agreement for Google and Verizon

Google has now entered into a patent cross selling agreement with Verizon after cutting similar deals with Cisco, Samsung and LG, in its pursuit to attain cutting-edge technology and fend off lawsuits. The contract will not give Google and Verizon access to each other’s patents, but will forbid them from filing lawsuits against each other over patent infringements of their existing patents as well as patents obtained by them over the next five years. The agreement will cover a wide…

January 5, 2015 BananaIP Reporter Intellectual Property, Patents 0Comment 910Views 0Like

ShareFacebook

Featherbed Frame: The Frame That is Revolutionizing Motorcycle Construction

This post was first published on 16th October, 2014. The chassis or the frame is part of a vehicle that is of paramount importance. It is like a skeleton that defines the shape of the vehicle and holds all the associated components of the vehicle together. There are different types of motorcycle frames such as single cradle, half duplex cradle, full duplex cradle, perimeter, beam, trellis etc., Though single cradle or single down-tube cradle frame is the simple and most commonly…

October 16, 2014 BananaIP Reporter Intellectual Property, Patents 0Comment 1563Views 0Like

ShareFacebook

Introduction to Patent Law – A Presentation at NLSIU

This presentation gives an overview of the patent and introduces students to the patent life cycle. It also delves briefly into justifications for patent protection. The presentation is available here. By Dr. Kalyan

December 26, 2013 BananaIP Reporter Intellectual Property, Patents 0Comment 701Views 0Like

ShareFacebook

The featured image shows many strips of tablets and a thermometer on a grey background. The post is regarding the trademark dispute between Cadila health care and Sun Pharma . To know more please click here.

The 3D Effect of Novartis Case on Genetic Inventions

The Novartis decision of the Indian Supreme Court rejecting patentability of the cancer drug, Imatinib Mesylate in its beta crystalline form (commonly called 'Glivac'), has been commended for its outlook on public interest and access to health. It was in fact an important decision for cancer patients as it removes the last possible hurdle to access the drug at one-tenth of its cost, which was around Rs. 1, 20, 000/- per month. The main issue in the case revolved around…